Grifols, S.A. GRF.MC
Healthcare · Drug Manufacturers - General · Spain · IBEX 35
Based on the available data, Grifols, S.A. gets an algorithmic score of 54/100. It trades at 9.61 €, with a bearish technical trend (RSI 47.5) and 28.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (9.5%).
- Low valuation (P/E 8.5).
- Meaningful dividend (87.00%).
Weaknesses
- —
Fundamentals
| P/E | 14.55 |
| Forward P/E | 8.45 |
| PEG | 0.24 |
| P/B | 1.18 |
| EV/EBITDA | 10.77 |
| P/S | 0.88 |
| ROE % | 6.93 |
| ROA % | 4.23 |
| Gross margin % | 37.79 |
| Operating margin % | 15.90 |
| Net margin % | 6.09 |
| Revenue growth % (y/y) | -0.90 |
| Earnings growth % (y/y) | 32.90 |
| Revenue CAGR % | 7.46 |
| Earnings CAGR % | 29.52 |
| Debt/Equity % | 117.24 |
| Current ratio | 2.37 |
| FCF yield % | 9.54 |
| Dividend yield % | 87.00 |
| Payout % | 35.21 |
Returns
| 1 month | -3.2 % |
| 3 months | +6.6 % |
| 6 months | +5.4 % |
| YTD | -13.3 % |
| 1 year | -22.6 % |
| 3 years | -17.8 % |
| 5 years | -51.7 % |
| 10 years | -42.3 % |
Risk
| 1-year volatility | 28.8 % |
| Beta | 1.07 |
| 5-year max drawdown | -65.4 % |
| Sharpe 1A | -0.88 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a Spanish company, it depends on ECB policy, the Spanish risk premium, the eurozone cycle and, if it operates in Latin America, on emerging-market currencies (BRL, MXN).
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.